{"prompt": "['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'TABLE OF CONTENTS', 'PAGE', '1. SYNOPSIS', '6', '2.', 'SCHEDULE OF ACTIVITIES (SOA)', '8', '3. INTRODUCTION', '11', '3.1.', 'Study Rationale', '11', '3.2.', 'Background', '12', '3.3.', 'Benefit/Risk Assessment', '13', '3.3.1.', 'Risk Assessment', '14', '3.3.2.', 'Benefit Assessment', '18', '3.3.3.', 'Overall Benefit:Risk Conclusion', '18', '4.', 'OBJECTIVES AND ENDPOINTS', '19', '5.', 'STUDY DESIGN', '20', '5.1.', 'Overall Design', '20', '5.2.', 'Number of Participants', '20', '5.3.', 'Participant and Study Completion', '21', '5.4.', 'Scientific Rationale for Study Design', '21', '5.5.', 'Dose Justification', '21', '6.', 'STUDY POPULATION', '22', '6.1.', 'Inclusion Criteria', '22', '6.2.', 'Exclusion Criteria', '23', '6.3.', 'Lifestyle Restrictions', '26', '6.3.1.', 'Meals and Dietary Restrictions', '26', '6.3.2.', 'Activity', '26', '6.4.', 'Screen Failures', '26', '7. TREATMENTS', '26', '7.1.', 'Treatments Administered', '27', '7.1.1.', 'Medical Devices', '27', '7.2.', 'Dose Modification', '28', '7.3.', 'Method of Treatment Assignment', '28', '7.4.', 'Blinding', '28', '7.5.', 'Preparation/Handling/Storage/Accountability', '28', '7.6.', 'Treatment Compliance', '29', '7.7.', 'Concomitant Therapy', '29', '7.8.', 'Treatment after the End of the Study', '31', '8.', 'DISCONTINUATION CRITERIA', '31', '8.1.', 'Discontinuation of Study Treatment', '31', '8.1.1.', 'Liver Chemistry Stopping Criteria', '31', '8.1.2.', 'QTc Stopping Criteria', '32', '8.1.3.', 'Neutrophil Stopping Criteria', '33', '8.1.4.', 'Temporary Discontinuation', '33', '8.1.5.', 'Study Treatment Restart', '33', '8.2.', 'Withdrawal from the Study', '33', '8.3.', 'Lost to Follow Up', '34', '3']['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '9. STUDY ASSESSMENTS AND PROCEDURES', '35', '9.1.', 'Efficacy Assessments', '35', '9.1.1.', 'FEV1', '35', '9.1.1.1.', 'Clinic Spirometry', '35', '9.1.1.2.', 'Mobile Spirometry', '35', '9.1.2.', 'SGRQ-C', '35', '9.1.3.', 'CAT', '36', '9.1.4.', 'COPD Exacerbations', '36', '9.1.5.', 'Patient Global Rating of Severity and Global Rating of', 'Change in Disease Severity', '36', '9.2.', 'Adverse Events', '37', '9.2.1.', 'Time Period and Frequency for Collecting AE and SAE', 'Information', '37', '9.2.2.', 'Method of Detecting AEs and SAEs', '37', '9.2.3.', 'Follow-up of AEs and SAEs', '37', '9.2.4.', 'Regulatory Reporting Requirements for SAEs', '38', '9.2.5.', 'Cardiovascular and Death Events', '38', '9.2.6.', 'Disease-Related Events and/or Disease-Related', 'Outcomes Not Qualifying as SAEs', '38', '9.2.7.', 'Pregnancy', '39', '9.2.8.', 'Medical Device Incidents (Including Malfunctions)', '39', '9.2.8.1.', 'Time Period for Detecting Medical Device', 'Incidents', '39', '9.2.8.2.', 'Follow-up of Medical Device Incidents', '40', '9.2.8.3.', 'Prompt Reporting of Medical Device Incidents', 'to Sponsor', '40', '9.2.8.4.', 'Regulatory Reporting Requirements for', 'Medical Device Incidents', '40', '9.3.', 'Treatment of Overdose', '41', '9.4.', 'Safety Assessments', '41', '9.4.1.', 'Physical Examinations', '41', '9.4.2.', 'Vital Signs', '41', '9.4.3.', 'Electrocardiograms', '42', '9.4.4.', 'Clinical Safety Laboratory Assessments', '42', '9.4.5.', 'Pneumonia', '42', '9.5.', 'Pharmacokinetics', '43', '9.6.', 'Pharmacodynamics', '43', '9.7.', 'Genetics', '43', '9.8.', 'Biomarkers', '43', '9.9.', 'Health Economics OR Medical Resource Utilization and Health', 'Economics', '44', '10. STATISTICAL CONSIDERATIONS', '44', '10.1. Sample Size Determination', '44', '10.2. Randomization', '47', '10.3. Populations for Analyses', '47', '10.4.', 'Statistical Analyses', '47', '10.4.1.', 'Efficacy Analyses', '47', '10.4.2.', 'Safety Analyses', '50', '10.4.3.', 'Other Analyses', '50', '10.4.4.', 'Interim Analyses', '50', '4']\n\n###\n\n", "completion": "END"}